Fertility remains a challenge for men with 5α-reductase-2 deficiency. Such a diagnosis was made in 2 adult brothers who are compound heterozygous for the 5α-reductase type 2 gene (SRD5A2; c.308G>C; c.689A>C). They were born with ambiguous genitalia and the male sex was assigned. Both brothers underwent reconstructive genital surgery during pediatric age and had spontaneous virilization at puberty. The older brother experienced natural conception, while the younger had a son by assisted reproductive technology. Other family members were demonstrated to be compound heterozygous or heterozygous for the same genetic variants. The older brother is the third man with 5α-reductase-2 deficiency and spontaneous paternity. The little series of men with 5α-reductase-2 deficiency and documented spontaneous or assisted paternity is reviewed. In conclusion, the possibility of fatherhood is a main indication for male sex assignment in patients with 5α-reductase-2 deficiency.

Baldinotti F, Majore S, Fogli A, Marrocco G, Ghirri P, et al: Molecular characterization of 6 unrelated Italian patients with 5-alpha-reductase type 2 deficiency. J Androl 29:20-28 (2008).
Cai LQ, Fratianni CM, Gautier T, Imperato-McGinley J: Dihydrotestosterone regulation of semen in male pseudohermaphrodites with 5-alpha-reductase-2 deficiency. J Clin Endocrinol Metab 79:409-414 (1994).
Cohen-Kettenis PT: Gender change in 46,XY persons with 5-alpha-reductase-2 deficiency and 17-beta-hydroxysteroid dehydrogenase-3 deficiency. Arch Sex Behav 34:399-410 (2005).
Costa EM, Domenice S, Sircili MH, Inacio M, Mendonca BB: DSD due to 5α-reductase 2 deficiency - from diagnosis to long term outcome. Semin Reprod Med 30:427-431 (2012).
Grumbach MM: A window of opportunity: the diagnosis of gonadotropin deficiency in the male infant. J Clin Endocrinol Metab 90:3122-3127 (2005).
Hadziselimovic F: On the descent of the epididymo-testicular unit, cryptorchidism, and prevention of infertility. Basic Clin Androl 27:21 (2017)
Hadziselimovic F, Dessouky N: Differences in testicular development between 5alpha-reductase 2 deficiency and isolated bilateral cryptorchidism. J Urol 180:1116-1120 (2008).
Hiort O, Reinecke S, Thyen U, Jürgensen M, Holterhus PM, et al: Puberty in disorders of somatosexual differentiation. J Pediatr Endocrinol Metab 16:297-306 (2003).
Hughes IA, Houk C, Ahmed SF, Lee PA: LWPES Consensus Group; ESPE Consensus Group. Consensus statement on management of intersex disorders. Arch Dis Child 91:554-653 (2006).
Ivarsson SA: 5-alpha reductase deficient men are fertile. Eur J Pediat 155:425 (1996).
Kang HJ, Imperato-McGinley J, Zhu YS, Cai LQ, Schlegel P, et al: The first successful paternity through in vitro fertilization-intracytoplasmic sperm injection with a man homozygous for the 5α-reductase-2 gene mutation. Fertil Steril 95:2125.e5-8 (2011).
Kang HJ, Imperato-McGinley J, Zhu YS, Rosenwaks Z: The effect of 5α-reductase-2 deficiency on human fertility. Fertil Steril 101:310-316 (2014).
Katz MD, Cai LQ, Zhu YS, Herrera C, De Fillo-Ricart M, et al: The biochemical and phenotypic characterization of females homozygous for 5 alpha-reductase-2 deficiency. J Clin Endocrinol Metab 80:3160-3167 (1995).
Katz MD, Kligman I, Cai LQ, Zhu YS, Fratianni CM, et al: Paternity by intrauterine insemination with sperm from a man with 5alpha-reductase-2 deficiency. N Engl J Med 336:994-997 (1997).
Maimoun L, Philibert P, Cammas B, Audran F, Bouchard P, et al: Phenotypical, biological, and molecular heterogeneity of 5α-reductase deficiency: an extensive international experience of 55 patients. J Clin Endocrinol Metab 96:296-307 (2011).
Matsubara K, Iwamoto H, Yoshida A, Ogata T: Semen analysis and successful paternity by intracytoplasmic sperm injection in a man with steroid 5α-reductase-2 deficiency. Fertil Steril 94:2770.e7-10 (2010).
Mendonca BB, Batista RL, Domenice S, Costa EM, Arnhold IJ, et al: Steroid 5α-reductase 2 deficiency. J Steroid Biochem Mol Biol 163:206-211 (2016).
Niedzielski JK, Oszukowska E, Słowikowska-Hilczer J: Undescended testis - current trends and guidelines: a review of the literature. Arch Med Sci 12:667-677 (2016).
Nordenskjöld A, Ivarsson SA: Molecular characterization of 5-alpha-reductase type 2 deficiency and fertility in a Swedish family. J Clin Endocrinol Metab 83:3236-3238 (1998).
Schwentner C, Oswald J, Kreczy A, Lunacek A, Bartsch G, et al: Neoadjuvant gonadotropin-releasing hormone therapy before surgery may improve the fertility index in undescended testes: a prospective randomized trial. J Urol 173:974-977 (2005).
Sotos JF, Tokar NJ: Testicular volumes revisited: a proposal for a simple clinical method that can closely match the volumes obtained by ultrasound and its clinical application. Int J Pediatr Endocrinol 2012:17 (2012).
Tekgül S, Dogan HS, Hoebeke P, Radmayr C, Bogaert G, et al: Management of undescended testes - European Association ofUrology/European Society for Paediatric Urology guidelines. Available at http://uroweb.org/guideline/paediatric-urology/ (assessed August 2018).
Thorup J, Cortes D: Surgical management of undescended testis: timetable and outcome Sex Dev 2019, in press.
Veale D, Miles S, Bramley S, Muir G, Hodsoll J: Am I normal? A systematic review and construction of nomograms for flaccid and erect penis length and circumference in up to 15,521 men. BJU International 115:978-986 (2015).
Wigley WC, Prihoda JS, Mowszowicz I, Mendonca BB, New MI, et al: Natural mutagenesis study of the human steroid 5 alpha-reductase2 isozyme. Biochemistry 33:1265-1270 (1994).
Wilson JD, Griffin JE, Russell DW: Steroid 5-alpha-reductase 2 deficiency. Endocr Rev 14:577-593 (1993).
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.